Manila, Philippines, Royal Philips (NYSE: PHG, AEX: PHIA) – Asian Hospital and Medical Center’s (AHMC) recently launched its Catheterization Lab that includes the next-generation image-guided therapy platform, Philips Azurion 7 C20. This next-generation image-guided therapy platform lets clinicians perform open and minimally invasive procedures in one room. The Azurion platform allows for easy and confident performance of a wide range of routine and complex procedures with a unique user experience, helping optimize laboratory performance and provide superior care for patients. The platform has high standards of safety and low radiation exposure that benefits both patients and staff using it. By 2030, Asia is expected to be home to over 60% of the total population aged 65 years or older1. As the range of diseases that can be treated with minimally invasive procedures continues to expand and the procedures themselves become more efficient, the patient’s treatment experience continues to improve. They experience less trauma, and as a result, their stay in hospital can be dramatically reduced – often returning home after one night in hospital, and for some procedures even leaving the hospital on the same day. Ashwin Chari, country manager of Philips Philippines Inc., said, “As patient volumes rise and procedures become more complex, the Philips Azurion‘s intuitive, outstanding user experience empowers doctors to have the ability to move quickly and confidently through procedures. Clinical excellence unites with workflow innovation to support clinicians in delivering outstanding patient care, reducing risk of complications and increasing operational efficiency.”
Andres Licaros, Jr., President and CEO of Asian Hospital and Medical said, “We, at AHMC want to provide world-class services through collaborations with our partners. Faced with a growing demand for image-guided therapy and increasingly complex procedures, we are looking for ways to treat more patients in less time without compromising quality of care. As one of the top hospitals in the country, it was natural for us to select the Philips Azurion to help us deliver innovative healthcare solutions to our patients.” Since its global launch in February 2017, over 450,000 patients have been treated in more than 80 countries using a Philips Azurion system. A two-year study found that clinicians’ use of Azurion enabled significant reductions in procedure time, in-lab patient preparation time, post-procedure lab time and enhanced staff experience1. Philips’ Image-Guided Therapy business offers integrated solutions comprising interventional imaging systems, smart catheters, planning and navigation software, and services with the aim to improve minimally invasive treatments. Worldwide, Philips’ Image-Guided Therapy solutions are helping to treat one patient every second.
Find out more about the Philips Azurion at https://www.philips.com.ph/
1 Deloitte Insights. Voice of Asia Report. Third Edition, September 2017.
2 https://www.philips.com/a-w/about/news/archive/standard/news/press/2017/20171114-new-study-demonstrates-significant-benefits-of-philips-azurion.html
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Senior Manager
Brand and Communications
Philips ASEAN Pacific